HEOR Policy Experts Present Drug Pricing Reform Options, Discuss FDA’s Accelerated Approval Mechanism and Pricing Negotiation
Health economics and outcomes research (HEOR) experts at the USC-Brookings Schaeffer Initiative for Health Policy and the Washington University School [...]
New JMCP Article on International Reference Pricing Assesses Global Models
Drs. Leah Rand and Aaron Kesselheim recently published an article in the Journal of Managed Care and Specialty Pharmacy (JMCP) [...]
Economists and Policy Experts Discuss Six Strategies to Address High Drug Costs
Paul Ginsberg and Steven Lieberman of the USC-Brookings Schaeffer Initiative for Health Policy discuss six policies that could address the [...]
Diabetes Drug Priced at $1349 per Month Leads to Weight Loss, Prompting Payer Coverage Debates
Wegovy, a type 2 diabetes drug that costs $1349 per month, can lead to weight loss. This side effect is [...]
Cost-Effective Insulin Glargine Biosimilar Could Upend Reference Diabetes Drug; McKinsey Estimates Biosimilar Market Will Hit $30 Billion by 2025
The Food and Drug Administration (FDA) recently approved Semglee, an insulin glargine biosimilar product. Compared to reference drug Lantus, the [...]
Pharma and Patient Advocacy Groups Release Expensive Ads Ahead of Drug Price Negotiation Bill
Patient and prescription drug pricing advocacy groups, including Patients for Affordable Drugs Now, are pushing for drug legislation using expensive [...]
Biden’s Prescription Drug Pricing Approach Pushes for Value-Based Pricing
President Joe Biden’s plan for lowering drug prices includes tying a drug’s price to its therapeutic value, according to recent [...]
Register Now for ICER’s Tuesday Webinar on Myasthenia Gravis Therapies
The Institute for Clinical and Economic Review (ICER) will hold a webinar on Tuesday, August 24th at 2:00 PM ET. [...]
Could Germany’s Proposed Drug Pricing Reform Impact United States?
The German committee responsible for assessing drug efficacy and setting prices may cut the initial 12-month review time by 50%. [...]
Researchers Claim Drug Price Limits Won’t Impact Innovation, PhRMA Strongly Disagrees
In a recently published article, researchers at Bentley University and West Health conclude that limiting drug prices will not affect [...]
Vanderbilt Scientist and Aetion RWE Strategist Highlight Seven Solutions to Bolster FDA’s Accelerated Approval Process and Achieve Value-Based Pricing
Aetion’s Dr. Nirosha Mahendraratnam Lederer and Vanderbilt’s Dr. Stacie B. Dusetzina discuss how value-based pricing may be achieved using the [...]
AIS Health’s RADAR on Drug Benefits Article Highlights Possible PBM Disruptor DomaniRx
AIS Health’s RADAR on Drug Benefits released an article on DomaniRx, a cloud-based pharmacy benefit manager (PBM) platform. The emerging [...]
National Academy of Sciences, Engineering and Medicine Released Pro-Pharma Report on $750 Million in Yearly Prescription Drug Waste Following Undisclosed Pharma Donations
Congress tasked the National Academy of Sciences, Engineering and Medicine with providing an impartial view of the $750 million in [...]
New Article Details $93.3 Billion Annual Costs in Drug Utilization Management
An article published in Health Affairs details the multibillion-dollar costs associated with inflated drug utilization management. The estimated $93.3 billion [...]
MMIT’s AIS Health Article Details Efficacy and Costs of Specialty Drugs
MMIT’s AIS Health recently published an article on specialty pharmacy. Employers are typically resistant to drugs commanding high price tags. [...]
Biden’s HHS Considers Eliminating Medicare Drug Pricing Model Reliant on International Benchmarks
The US Department of Health and Human Services (HHS) is considering doing away with a Medicare drug pricing model established [...]
Wyden’s Principles of Reform Include a US-Based Drug Pricing System
Senator Wyden is pushing for legislation that will reduce prescription drug prices, such as Biogen’s pricy Aduhelm. He’s noted that [...]
10-Year Hydrocortisone Tablet Overcharge and Pay-For-Delay Deal Lead to £266.4 Million in Fines
The UK Competition and Markets Authority (CMA) has fined hydrocortisone tablet manufacturers £266.4 million for overcharging the National Health Service [...]
New ISPOR Article Discusses Survey on the Impact of COVID-19 on HTAs and Payers
A new article, published in ISPOR’s Value in Health journal, discusses how the COVID-19 pandemic has impacted health technology assessments [...]
Wyden Seeks to Include Medicare Price Negotiation in Healthcare Legislation
Senate Finance Committee Chair Ron Wyden was adamant in his support for legislation that would allow Medicare to negotiate drug [...]
UK Seeks to Advance Cost-Effective Rare Disease Research, Allocates $340 Million to New Innovative Medicines Fund
The UK will expand its Cancer Drugs Fund by creating a new Innovative Medicines Fund. The fund will promote research [...]
I-MAK Co-Founder Discusses How the COVID-19 Pandemic Shed Light on Racial Inequities and Using the Patent System to Reduce Drug Prices
Co-Founder and Executive Director of the Initiative for Medicines, Access & Knowledge (I-MAK) Priti Krishtel shares her thoughts on how [...]
US Supreme Court to Consider Medicare Drug Pricing Challenge
The Supreme Court will consider a challenge brought forth by safety net hospitals. A Trump-era ruling leading to reduced drug [...]
Payers Must Cover HIV Prevention Drugs Without Cost-Sharing in Two Months
Federal regulations will require payers to cover HIV prevention drugs and care. Gilead’s HIV drug Truvada has faced criticism due [...]
Voters Seek to Maintain Access to Medication Through Medicare
A recent poll showed that voters strongly support access to prescription drugs through Medicare Part D. In addition, voters are [...]